GeneDx Holdings Corp.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GENEDX HOLDINGS CORP. | |||
| Date: | February 23, 2026 | By: | /s/ Katherine Stueland |
|---|---|---|---|
| Name: | Katherine Stueland | ||
| Title: | Chief Executive Officer and Director(Principal Executive Officer) | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Katherine Stueland, Kevin Feeley and Heidi Chen, and each or any one of them, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the United States Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Katherine Stueland | Chief Executive Officer and Director | February 23, 2026 |
| Katherine Stueland | (Principal Executive Officer) | |
| /s/ Kevin Feeley | Chief Financial Officer | February 23, 2026 |
| Kevin Feeley | (Principal Financial Officer) | |
| /s/ Jason Ryan | Chairman of the Board | February 23, 2026 |
| Jason Ryan | ||
| /s/ Eli D. Casdin | Director | February 23, 2026 |
| Eli D. Casdin | ||
| /s/ Emily Leproust | Director | February 23, 2026 |
| Emily Leproust | ||
| /s/ Keith Meister | Director | February 23, 2026 |
| Keith Meister | ||
| /s/ Joshua Ruch | Director | February 23, 2026 |
| Joshua Ruch | ||
| /s/ Richard Pfenninger, Jr. | Director | February 23, 2026 |
| Richard Pfenninger, Jr. | ||
| /s/ Thomas Fuchs | Director | February 23, 2026 |
| Thomas Fuchs | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.